Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects September 2, 2021 Irvin Jackson Add Your Comments The FDA has decided to require new label warnings about potential side effects of Xeljanz and other new-generation arthritis drugs from the same class, indicating users may face an increased risk of heart attacks, strokes, cancer, blood clots and death. In a drug safety communication issued on September 1, the agency announced it has completed a review of a large randomized clinical trial into Xeljanz, determining that side effects may include an increased risk of serious heart-related problems, cancer, pulmonary embolism and fatalities. As a result of the serious risk, new Xeljanz FDA label warnings are being required to alert the medical community and patients to the potential risks associated with Xeljanz and Xeljanx XR (tofacitinib), which are sold by Pfizer for treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. It was the first member of a new class of treatments known as JAK inhibitors, which also include Olumiant and Rinvoq, which will also be required to carry the heart, cancer and blood clot warnings. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION After Xeljanz was introduced in 2012, Pfizer aggressively marketed the drug, joining a lucrative market for rheumatoid arthritis treatments, which already included blockbuster drugs like Humira, Enbrel and other similar medications, known as tumor necrosis factor (TNF) inhibitors. Xeljanz was advertised as a safer and more convenient treatment option, and quickly grew to become a top selling drug, with annual sales of more than $2 billion worldwide. However, data from a recently completed study raised questions about serious Xeljanz side effects that were not adequately described on the drug’s warning label. In February 2021, the FDA issued a safety communication about a potential link between Xeljanz and cancer, heart attacks and other cardiovascular heart risks, following a preliminary review of data from a recently completed post-marketing study. The new communication issued this week updates those warnings, following the completion of the FDA’s full safety review. Originally, the agency thought the risks might be only associated with larger doses of Xeljanz. However, now the agency indicates that the same risks appear to exist for users of lower doses of Xeljanz as well. The FDA also clarified the Xeljanz cancer risk, indicating that there were particularly high rates of certain types of cancers, such as lymphomas and lung cancer, when compared to patients treated with TNF blockers. The higher rate of lung cancer among Xeljanz users appears to be among current or past smokers, compared to current or past smokers who took older TNF blockers. Other Arthritis Drugs To Carry Similar Warnings In addition to Xeljanz, the FDA will require new and updated warnings for two other JAK inhibitors, including Olumiant and Rinvoq. “Olumiant and Rinvoq have not been studied in trials similar to the large safety clinical trial with Xeljanz, so the risks have not been adequately evaluated,” the FDA communication notes. “However, since they share mechanisms of action with Xeljanz, FDA considers that these medicines may have similar risks as seen in the Xeljanz safety trial.” The agency noted it did not require warnings of two other JAK inhibitors, Jakafi and Inrebic. They are not indicated for the treatment of arthritis or other inflammatory conditions, and are used to treat blood disorders, which requires different updates to their prescribing information, according to the FDA. However, the agency notes if it becomes aware of any additional safety information or data which warrants updates to their label warnings, it will take further action and alert the public. The FDA warning requirements come following months of speculation after the agency held up approval of other JAK inhibitors, requiring more study data from the manufacturers. In June, Abbvie announced expanded approval for Rinvoq was being held up due to similar problems. Before that, in April, Pfizer announced the review for its new oral JAK inhibitor, abrocitinib, had been extended by three months due to the same concerns. In July, media reports indicated Lilly and Incyte also announced the FDA delayed approval of Olumiant; a rheumatoid arthritis drug seeking expanded approval as an Eczema treatment. It has already been approved to treat the skin condition in 40 countries. The study behind the FDA’s Xeljanz concerns was initially launched in January 2012, and given the long latency period for many cancers, many users now face concerns they require on-going medical monitoring to detect and diagnose cases in the future. Former users are now contacting lawyers who are investigating Xeljanz lawsuits and class action claims, to seek additional information which has not been disclosed and compensation for treatments they may now require. Tags: AbbVie, Arthritis, Blood Clots, Cancer, Eli Lilly, Heart Attack, Incyte, Lung Cancer, Olumiant, Pfizer, Rinvoq, Stroke, Ulcerative Colitis, Xeljanz More Xeljanz Lawsuit Stories Xeljanz Side Effects May Cause Weight Gain: Study May 22, 2025 Side Effects of Xeljanz, Rinvoq and Similar Drugs May Increase Risk of Acne: Study November 8, 2023 Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors May 1, 2023 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: 2 days ago) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025) Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 4 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024) Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 5 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)
Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors May 1, 2023
Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: 2 days ago) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025)
Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 4 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024)
Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 5 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)